On March 25, 2021, it was announced that duvelisib received a positive opinion from the European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) for the treatment of relapsed or refractory (R/R) chronic lymphocytic leukemia (CLL) and refractory follicular lymphoma (FL).1
Duvelisib is a dual inhibitor of PI3K-δ and PI3K-γ; therefore, it blocks the proliferation and survival of malignant B-cell lines and primary CLL tumor cells, as well as immunological pathways in the tumor microenvironment of malignant B cells.1
Duvelisib has already been granted approval by the U.S. Food and Drug Administration (FDA) for patients with R/R FL and patients with R/R CLL or small lymphocytic lymphoma, which was based on the DYNAMO (NCT01882803) and DUO (NCT02004522) trial results.2